Skip to content


  • Poster presentation
  • Open Access

Delivering a drug study in primary care: trial management challenges and solutions

  • 1,
  • 1,
  • 1 and
  • 1
Trials201516 (Suppl 2) :P179

  • Published:


  • Primary Care
  • Chronic Obstructive Pulmonary Disease
  • Theophylline
  • Study Medication
  • Secondary Care

The NIHR HTA funded TWICS trial is investigating whether low-dose theophylline (as an adjunct to existing inhaled corticosteroids) reduces exacerbations in patients with Chronic Obstructive Pulmonary Disease. It is a pragmatic, double-blind, randomised controlled trial aiming to recruit 1424 participants; with at least 50% from primary care. The trial was therefore designed to be delivered in both primary and secondary care settings. We will present some of the challenges that we have faced, together with the solutions we have implemented: two of these are described below.

There are challenges around delivery of the intervention. Over the 12 month follow-up, participants receive 13 bottles of once or twice daily study medication. For participants recruited in secondary care sites, the first of these bottles is dispensed from the site's clinical trials pharmacy; for those recruited in primary care, it is dispensed from the lead site's clinical trials pharmacy and couriered to their home. For all participants, all subsequent supplies of study medication are couriered direct to their home. We have now recruited 650 participants, all of whom have received their supplies of study medication.

There are also challenges around training and initiation of multiple primary care sites, which are needed to meet the primary care recruitment target. We have adopted a “train the trainer” model and have a network of research nurses who can deliver study training to primary care practices across the North and East of England. To date, they have trained > 75 primary care practices to deliver the study.

Authors’ Affiliations

University of Aberdeen, Aberdeen, UK


© Cotton et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.